The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

U.S. Health Secretary Robert F. Kennedy Jr’s newly appointed Advisory Committee on Immunization Practices (ACIP) upheld ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...